Rheumatology Symposium: Advances in the Diagnosis and Treatment of the Rheumatic Diseases

COURSE DESCRIPTION

This two-day activity has been planned for the providers of care to patients with rheumatic diseases. Given the variety of existing rheumatologic disorders as well as the numerous available diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of rheumatologic disorders, novel state-of-the-art diagnostic tools and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.

This activity is intended for rheumatologists, internists, family practitioners and other allied health professionals.

COURSE OBJECTIVES

Following this activity, the participant should be able to:

discuss and understand recent advances in the use of both non-biologic and biologic agents in the treatment of rheumatoid arthritis
understand the potential cardiovascular risks associated with both traditional NSAIDS and the COX-2 inhibitors
appreciate how new imaging modalities including MRI aid in the diagnosis and in the management of the rheumatic diseases
learn how to manage the rheumatic diseases during pregnancy
discuss new and emerging options for the treatment of gout
recognize the major cutaneous and oral manifestations of the rheumatic diseases.
discuss the impact of anti-TNF therapy in the treatment of both psoriatic arthritis and ankylosing spondylitis
appreciate advances in treatment for the systemic rheumatic diseases

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

NOTICE ABOUT OFF-LABEL USE PRESENTATIONS

The Johns Hopkins University School of Medicine Advances in the Diagnosis and Treatment of the Rheumatic Diseases may include presentations on drugs or devices, or use of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.

All rights reserved. No part of this presentation/material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

COURSE DIRECTORS

Joan M. Bathon, MD
Professor of Medicine
Division of Rheumatology
Director, Johns Hopkins Arthritis Center

Stuart Levine, MD
Assistant Professor of Medicine
Division of Rheumatology

Antony Rosen , MD
Professor of Medicine
Division of Rheumatology
Director, Division of Rheumatology

JOHNS HOPKINS FACULTY

Grant Anhalt, MD, FRCPC
Professor of Medicine and of Dermatology
Vice Chairman,
Department of Dermatology

David A. Bluemke, MD, PhD
Associate Professor of Radiology and
Radiological Science

Lisa Christopher-Stine, MD, MPH
Assistant Professor of Medicine
Division of Rheumatology

John A. Flynn, MD, MBA
Associate Professor of Medicine
Division of Rheumatology

Kevin Fontaine, PhD
Assistant Professor of Medicine
Division of Rheumatology

Allan Gelber, MD, MPH, PhD
Associate Professor of Medicine
Division of Rheumatology

Uzma Haque , MD
Assistant Professor of Medicine
Division of Rheumatology

Laura Hummers, MD
Assistant Professor of Medicine
Division of Rheumatology

Suzanne M. Jan De Beur, MD
Assistant Professor of Medicine
Division of Endocrinology

Alan K. Matsumoto, MD
Assistant Professor of Medicine
Division of Rheumatology

Michelle Petri, MD, MPH
Professor of Medicine
Division of Rheumatology
Director, Johns Hopkins Lupus Center

James Sciubba, MD
Professor of Medicine
Department of Otolaryngology –
Head and Neck Surgery

John H. Stone, MD, MPH
Associate Professor of Medicine
Division of Rheumatology

GUEST FACULTY

Steve Abramson, MD
Associate Dean for Clinical Research
Professor of Medicine and Pathology
New York University Medical Center
New York , New York

John Carrino, MD, MPH
Assistant Professor of Radiology
Harvard Medical School
Co-Director,
Radiology Spine Intervention Service
Brigham and Women's Hospital
Boston , Massachusetts

Daniel Clauw, MD
Assistant Dean Clinical and
Translational Research
Professor of Internal Medicine
University of Michigan Medical School
Ann Arbor , Michigan

Megan Clowse, MD, MPH
Assistant Professor of Medicine
Duke University Medical Center
Durham , North Carolina

Robert Wortmann, MD, FACR
Professor and Chairman of
Internal Medicine Department
University of Oklahoma College of Medicine
Tulsa , Oklahoma

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

Advances in the Diagnosis and Treatment of the Rheumatic Diseases
Baltimore , Maryland
June 5 - 6, 2006

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

NAME	COMPANY
Steven Abramson, MD	Consultant: Pfizer; Novartis
Grant Anhalt, MD	Grants/Research Support/Consultant: Asprena Pharmaceuticals
Joan M. Bathon , MD	Grants: Biogen/IDEC; Bristol Myers Squibb; Roche Consultant: Centocor Honorarium: Amgen; Biogen; Wyeth
David A. Bluemke, MD, PhD	Grants/ResearchSupport: Epix Medical, Toshiba
John C. Davis , MD, MPH	Grants: Amgen; Abbott, Centocor
John A. Flynn , MD, MBA	Grants: NIH; Abbott
Suzanne M. Jan De Beur , MD	Honorarium: Procter and Gamble
Michelle A. Petri , MD, MPH	Grants: Genelabs; Human Genome Sciences; Medimmune; Immunogenetics; TEVA; Pfizer, Inc. Consultant: Amgen Honorarium: Genentech Speakers Bureau
Fredrick M. Wigley , MD	Grants: Otsuka; Mediquest; Biogen/IDEC Consultant: Genzyme; Norvartis; Actelion
Robert Wortmann , MD,FACR	Consultant: TAP Pharmaceuticals

All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

NAME	PRODUCT
Gant Anhalt , MD	Pemphgus – Cell Cept, Ritvxan; Invlg.; azathloprine
David A. Bluemke, MD, PhD	Gadolinium enhanced MRI
Lisa Christopher-Stine , MD, MPH	cellcept; Tacrolimus; cyclosporine; sirolimus; rituximab; ZVIG; etanercept
John C. Davis , MD,MPH	Adalimumab for AS
Laura K. Hummers , MD	cyclophosphamide; mycophendate mofetil; alafacept; cyclosporine; tacrolimus; sirdimus
Suzanne M. Jan De Beur , MD	use of IV zolendronate for ostoeporosis
Michelle A. Petri , MD, MPH	all products will be off-label except for predniscne and plaquenil.
Robert Wortmann , MD,FACR	Fenofibrate, cosartan

All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.